What's breaking now, across thousands of outlets.
Inhibrx Biosciences says its latest mid-stage results show the potential of its OX40 agonist in immunogenic cancers — but also its prospects in combination with cancer vaccines in tumors with lower immunogenicity. “The next step for ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
“Pushing this is like a rock up a hill, because there’s been so much failure in the space,” said Inhibrx CEO Mark Lappe.
Maharashtra is eyeing a larger role in global healthcare innovation by leveraging the India-UK CETA to attract investment, technology and partnerships, with the state’s strong pharma, medtech and…
A societal spotlight on extreme thinness is stripping body diversity from screens, just as fashion magazines did in the early aughts, mental health experts tell Axios.
A new wave of illegal fruity vapes, more and more kids on GLP-1s, and other health news from Morning Rounds
Despite nearly 1.3 million deaths and counting, there is still not a national memorial for the pandemic. Our informal memorial in the middle of the Mojave Desert is one small way to remember those…
Patients of disgraced brain surgeon Sam Eljamel were left with "horrific" disabilities following his operations, a former MSP has told an inquiry.
